Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EPS (Basic) (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EPS (Basic) for 16 consecutive years, with -$0.06 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 700.0% to -$0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.28 through Dec 2025, down 357.14% year-over-year, with the annual reading at -$1.28 for FY2025, 357.14% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.06 at Harvard Bioscience, down from -$0.03 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.06 in Q2 2022, with the low at -$4.17 in Q3 2021.
  • Average EPS (Basic) over 5 years is -$0.3, with a median of -$0.04 recorded in 2022.
  • The sharpest move saw EPS (Basic) plummeted 13804.57% in 2021, then skyrocketed 700.0% in 2022.
  • Over 5 years, EPS (Basic) stood at $0.02 in 2021, then tumbled by 300.0% to -$0.04 in 2022, then grew by 0.0% to -$0.04 in 2023, then soared by 125.0% to $0.01 in 2024, then tumbled by 700.0% to -$0.06 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.06, -$0.03, and -$0.05 for Q4 2025, Q3 2025, and Q2 2025 respectively.